Stockreport

Buy Altimmune's Potential Market Disruption With Pemvidutide [Seeking Alpha]

Altimmune, Inc.  (ALT) 
NASDAQ:AMEX Investor Relations: altimmune.com/investors
PDF Their lead drug candidate, Pemvidutide, targets glucagon-like peptide-1 and glucagon receptors to produce weight loss with reduced side effects. Pemvidutide has shown [Read more]